Stock Market & Financial Investment News

News Breaks February 19, 2013 06:16 EDT NVS Novartis won't give outgoing chairman $77.98 pay package, Reuters reports Novartis (NVS) said it would drop a $77.98M pay package for the outgoing chairman Daniel Vasella, as it reacts to growing anger in Switzerland before an investor meeting this Friday, reports Reuters. Reference Link News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 16:20 EDT NVS Novartis drug Afinitor extended time without disease progression in women Subscribe for More Information May 16, 2013 08:11 EDT NVS Novartis says no intention of pursuing Actavis, Bloomberg reports Subscribe for More Information May 15, 2013 19:37 EDT NVS Novartis weighing Actavis bid, WSJ reports Subscribe for More Information 18:17 EDT NVS Novartis weighs possible bid for Actavis, DJ reports Subscribe for More Information May 10, 2013 05:42 EDT NVS Novartis drug Ilaris approved by FDA Subscribe for More Information May 6, 2013 16:23 EDT NVS Array to start first company-led Phase 3 trial with MEK162 Array (ARRY) announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer. This is the third MEK162 pivotal trial that is expected to initiate in 2013 and one of five pivotal trials Array expects to begin in 2013 on Array-invented products. Novartis (NVS), who is co-developing MEK162 with Array, previously stated that Phase 3 trials in NRAS-mutant melanoma and BRAF-mutant melanoma are expected to start this year and AstraZeneca has announced its plans to initiate two registration trials with selumetinib, a MEK inhibitor invente (AZN) d by Array, in KRAS-mutant non-small cell lung cancer and in thyroid cancer. Array also recently released initial data on its wholly-owned hematology drug, ARRY-520, from a combination trial with VelcadeŽ (bortezomib) in patients with relapsed or refractory multiple myeloma (MM), showing that the drug was generally well-tolerated and showed initial signs of activity in this heavily pretreated population. Sign up for a free trial to see the rest of the stories you've been missing.